论文部分内容阅读
Ｗａｒｎｅｒ Ｌａｍｂｅｒｔ公司已中止了喹诺酮类抗生素克林沙星 (ｃｌｉｎａｆｌｏｘａｃｉｎ)的开发 ,并放弃了其用于医院内严重感染治疗的美国上市申请。在过去的一年里 ,ＦＤＡ对本品可能的不良反应 ,如肝脏毒性和心律失常等表示关注 ,而这些不良反应难以回顾性地从临床
Warner Lambert has discontinued the development of the quinolone antibiotic clinafloxacin and has abandoned its US-listed application for the treatment of severe infections in hospitals. In the past year, the FDA expressed concern about potential side effects such as liver toxicity and arrhythmia, which are difficult to retrospectively recover from clinical